NCT01082536

Brief Summary

The purpose of this study is to use an experimental diagnostic tool(NIRS), combined with a known screening tool (cranial ultrasound), to analyze and evaluate cerebral blood flow and oxygenation, and determine if abnormal neurodevelopmental outcomes can be predicted and potentially improved upon in pediatric patients undergoing repair for congenital heart disease.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Mar 2013

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 5, 2010

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 8, 2010

Completed
3.1 years until next milestone

Study Start

First participant enrolled

March 28, 2013

Completed
6.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2019

Completed
Last Updated

January 31, 2019

Status Verified

January 1, 2019

Enrollment Period

6.1 years

First QC Date

March 5, 2010

Last Update Submit

January 29, 2019

Conditions

Keywords

PediatricsCongenital heart diseaseNIRSBrain oxygenation

Outcome Measures

Primary Outcomes (1)

  • To determine if the use of cranial ultrasound and multi-source-detector near infrared spectroscopy can identify alterations in cerebral perfusion that are associated with long-term neurologic dysfunction.

    Using multi-channel NIRS and pre-, intra-, and post-operative ultrasound, we will measure blood oxygenation levels and try to correlate these levels with 12 month neuropsychological evaluation.

    12 months

Secondary Outcomes (2)

  • 2. Evaluate whether changes in resistive indices as determined by cranial ultrasound after cardiopulmonary bypass are associated with major neurologic dysfunction.

    12 months

  • 3. Describe regional changes in brain tissue oxygenation during selective cerebral perfusion using near-infrared spectroscopy and determine if there are critical thresholds that correlate with poor neurologic outcomes.

    12 months

Study Arms (6)

One ventricle pts, bypass, perfusion

1\. Single ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.

One ventricle pts, bypass only

Single ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion

One ventricle pts, no bypass/perfusion

Single ventricle patients who undergo surgery, but do not undergo cardiopulmonary bypass or selective cerebral perfusion.

Two ventricle pts, bypass, perfusion

Two ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.

Two ventricle pts, bypass only

Two ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion.

Two ventricle pts, no bypass/perfusion

Two ventricle patients who do not undergo cardiopulmonary bypass or selective cerebral perfusion.

Eligibility Criteria

AgeUp to 2 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Infants (up to 2 months) with congenital heart disease that undergo surgery at Children's Medical Center Dallas (CMCD) will be eligible. All such patients will receive standard pre-, intra-, and post-operative care.

You may qualify if:

  • Is less than 2 months of age
  • Has congenital heart disease requiring surgical repair.
  • All racial and ethnic groups will be eligible. Both genders are eligible.
  • Spanish-speaking subjects are eligible.

You may not qualify if:

  • Patients with known genetic syndromes will be excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's Medical Center Dallas

Dallas, Texas, 75235, United States

Location

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood

MeSH Terms

Conditions

Heart Defects, Congenital

Condition Hierarchy (Ancestors)

Cardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Nancy Rollins, MD

    UT Southwestern Medical Center at Dallas

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

March 5, 2010

First Posted

March 8, 2010

Study Start

March 28, 2013

Primary Completion

May 1, 2019

Study Completion

May 1, 2019

Last Updated

January 31, 2019

Record last verified: 2019-01

Locations